ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip OA

9 Steps to Transform Your Rheumatology Practice

Erin Arnold, MD; William Arnold, MD; Gary Crump, MD; David Sikes, MD; Drew Johnson, MS, MBA; & Timothy Harrington, MD  |  August 12, 2020

The ACR position statement on access to care proposes the goal that “… all patients have timely access to expert rheuma­tology care … .”1 The reality is that new and established rheumatology patient wait times are often prolonged, causing delays in necessary diagnosis and treatment. The 2005 and 2015 ACR Workforce studies document intractable and…

Filed under:Practice SupportSpeak Out RheumWorkforce Tagged with:Advanced Practice CliniciansAssociation of Rheumatology Professionals (ARP)Rheumatoid Arthritis Practice PerformanceSpeak Out RheumatologyTreat-to-Targetworkforce shortage

The Problem with Peer Review

Philip Seo, MD, MHS  |  August 12, 2020

I should have paid more attention in medical school. If I had, I might have remembered enough about basic pathophysiology to know why everyone was suddenly pulling their patients off of lisinopril. For those of you who need a quick primer: When the pressure in the renal artery drops, the kidney secretes renin. Working together,…

Filed under:OpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:Peer reviewResearch

MIA Studio / shutterstock.com

ACR Releases COVID-19 & MIS-C Clinical Guidance for Kids with Rheumatic Disease

Gretchen Henkel  |  August 12, 2020

The ACR has released clinical guidance documents for pediatric patients with rheumatic disease in the context of the COVID-19 pandemic, including one for multi-system inflammatory syndrome in children (MIS-C). Jay Mehta, MD, MS, an attending physician in the Division of Rheumatology and director of the Pediatric Rheumatology Fellowship at the Children’s Hospital of Philadelphia (CHOP),…

Filed under:ConditionsPediatric Conditions Tagged with:COVID-19Jay MehtaLauren HendersonMultisystem Inflammatory Syndrome in Children (MIS-C)Pediatric Rheumatology

Bisphosphonates Reduce Bone Toughness Over Time

Will Boggs, MD  |  August 11, 2020

NEW YORK (Reuters Health)—Using bisphosphonates for several years is associated with increasing brittleness and decreasing toughness of bone, according to a new review. “Long-term treatment with bisphosphonates can have negative side effects in some people because of their effects on bone toughness [toughness = the energy that bone tissue can absorb before cracking],” David B….

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesbonebone mineral density (BMD)FracturesOsteoporosisosteoporosis treatments

NIH Taps Lindsey Criswell, MD, MPH, DSc, as Director of NIAMS

National Institutes of Health  |  August 11, 2020

National Institutes of Health Director Francis S. Collins, MD, PhD, has selected Lindsey A. Criswell, MD, MPH, DSc, as director of NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). A rheumatologist, Dr. Criswell is currently the vice chancellor of research at the University of California, San Francisco (UCSF). She is a professor…

Filed under:Professional Topics Tagged with:Lindsey A. CriswellNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIAMSNIH

Abaloparatide vs. Alendronate for Osteoporosis

Lara C. Pullen, PhD  |  August 10, 2020

In a clinical trial, researchers compared the efficacy of abaloparatide with alendronate in reducing the risk of fracture among postmenopausal women with osteoporosis. The findings suggest initial treatment with abaloparatide may result in greater vertebral fracture reduction than alendronate…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:abaloparatidealendronateFracturesOsteoporosisosteoporosis treatments

The ACR Expresses Strong Support for Dr. Anthony Fauci

From the College  |  July 29, 2020

The ACR, on behalf of its more than 7,700 members of the professional rheumatology community, wishes to express strong support for Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), and his continued and close involvement in the work to address the nation’s response to the COVID-19 pandemic. During…

Filed under:Professional Topics Tagged with:ACR Convergence 2020Anthony S. FauciCOVID-19

Denosumab Dosing Delays Tied to Increased Fracture Risk

Megan Brooks  |  July 27, 2020

NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabfracture riskFracturesOsteoporosisosteoporosis treatments

How to Empower Lupus Patients Through Social Media & Online Resources

Carina Stanton  |  July 27, 2020

Social media connections, such as LupusChat and online resources from the ACR’s Lupus Initiative, are providing safe spaces and support for lupus patients during the COVID-19 pandemic…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:communityLupusChatpatient careself-managmentSocial Mediasupportsystemic lupus erythematosus (SLE)

RheumPAC Supports Rheumatology Through the Pandemic

Kurt Ullman  |  July 17, 2020

With usual in-person fundraisers and meetings not possible during the pandemic, RheumPAC is finding creative ways to keep advocating for influential legislation and ensure rheumatology’s voice is heard in Washington, D.C.

Filed under:Legislation & Advocacy Tagged with:COVID-19RheumPAC

  • « Previous Page
  • 1
  • …
  • 125
  • 126
  • 127
  • 128
  • 129
  • …
  • 337
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences